
‘We Are Not Programmed to Die,' Says Nobel Laureate Venki Ramakrishnan
Apr 15, 2025 5:00 AM The structural biologist, who has devoted his life to studying the processes behind aging, discusses the surprising things he has learned and the public misunderstandings about longevity. Venkatraman Ramakrishnan at the Milan Longevity Summit in Milan, Italy. Courtesy of the Milan Longevity Summit
If you buy something using links in our stories, we may earn a commission. Learn more.
Venkatraman Ramakrishnan, the man of death. Although this does not sound like a good moniker, it is: Ramakrishnan is one of the world's most eminent scientists in the fields of structural biology and cellular processes related to aging and death. He was awarded the Nobel Prize in Chemistry in 2009 for his discovery of the structure of the ribosome, a crucial cellular machine responsible for gene expression.
In addition to being a leading researcher, Ramakrishnan is also a prolific author. After the enormous success of The Gene Machine , a memoir in which he recounts his human and scientific journey, he published the mighty Why We Die , a book—as its name suggests—dedicated precisely to illustrating the dynamics that regulate aging and which, progressively and inexorably, lead to death.
Ramakrishnan was recently in Italy, in Milan, where he gave a lecture at the second edition of the Milan Longevity Summit, the most important Italian event dedicated to longevity and psycho-physical well-being, organized by BrainCircle Italia. It was an opportunity to meet him and ask him a few questions. This interview has been edited for clarity and length.
WIRED: Professor Ramakrishnan, the crucial question in your book is why we die . But exactly what is death?
Venki Ramakrishnan: By death, we mean the irreversible loss of the ability to function as a coherent individual. It is the result of the failure of a critical system or apparatus, for example, heart, brain, lung, or kidney failure. In this sense there is an apparent paradox: When our organism, as a whole, is alive, millions of cells within us are constantly dying, and we do not even realize it. On the other hand, at the time of death, most of the cells in our bodies are still alive, and entire organs are still functioning and can be donated to people in need of transplantation. But at that point the body has lost the ability to function as a whole. In this sense, it is therefore important to distinguish between cell death and death of the individual.
Speaking of death and aging, you say in your most recent book that you 'wanted to offer an objective look at our current understanding of the two phenomena.' What was the biggest surprise or most deeply held belief that you had to reconsider while writing and researching this work?
There have been several surprises, actually. One is that death, contrary to what one might think, is not programmed by our genes. Evolution does not care how long we live, but merely selects the ability to pass on our genes, a process known as 'fitness' in evolutionary biology. Thus, the traits that are selected are those that help us survive childhood and reproduce. And it is these traits, later in life, that cause aging and decline.
Another curious finding was the fact that aging is not simply due to wear and tear on cells. Wear and tear happens constantly in all living things, yet different species have very different lifespans. Instead, lifespan is the result of a balance between the expenditure of resources needed to keep the organism functioning and repairing it and those needed to make it grow, mature, and keep it healthy until it reproduces and nurtures offspring.
Do you think there is an aspect of the biology of aging that is still deeply misunderstood by the general public?
Certainly the indefinite extension of life. Although in principle there are no laws or constraints that prevent us from living much longer than we do currently, great longevity or 'eternal youth' are still far off, and very significant obstacles to increasing our maximum life expectancy remain.
We must also beware of the pseudoscience—and business—around the concepts of 'anti-aging' or the 'reversal of aging.' These are often baseless concepts, unsupported by hard evidence, even though they may use language that sounds scientific. Unfortunately, we are all afraid of growing old and dying, so we are very sensitive to any claim that promises to help us avoid it.
A famous scene in the movie Frankenstein Junior shows a student asking Professor Frankenstein about some experiments with worms, and the lecturer replies that 'a worm, with very few exceptions, is not a human being.' Yet a whole chapter of Why We Die is called 'Lessons from a Humble Worm.' What do we have to learn from worms?
Science has always studied fundamental processes by using model organisms, including worms, fruit flies, and even yeast and bacteria. Of course, the closer these species are to us, the better, which is why drug trials are first conducted on mice and even monkeys and chimpanzees. But we can learn a lot from organisms like the worm. Many things discovered in worms have counterparts in humans. However, we cannot directly extrapolate every result. For example, humans with some of the same mutations that cause the longevity of worms turn out to have serious problems, such as growth defects.
What do you think are the social and ethical implications of our desire to live longer?
Ever since we became aware of our mortality, we have desired to defeat aging and death. However, our individual desires may conflict with what is best for society. A society in which fertility rates are very low and lifespans are very high will be a stagnant society, with very slow generational turnover, and probably much less dynamic and creative. The Nobel Prize-winning South American novelist Mario Vargas Llosa, who recently passed away, expressed it best: 'Old age on the one hand terrifies us, but when we feel anxious, it is important to remember how terrible it would be to live forever. If eternity were guaranteed, all the incentives and illusions of life would vanish. This thought can help us live old age in a better way.'
This story originally appeared on WIRED Italia and has been translated from Italian.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Los Angeles Times
14 hours ago
- Los Angeles Times
First millennial saint Carlo Acutis will be canonized Sept. 7, the pope says
ROME — Pope Leo XIV on Friday set Sept. 7 as the rescheduled date to canonize the Catholic Church's first millennial-era saint, Carlo Acutis, in what is expected to be Leo's first saint-making ceremony as well. Leo made the announcement during a meeting of cardinals, known as a consistory, to set the dates for a handful of new saints. Acutis' canonization was originally scheduled for April 27, but was postponed following the death of Pope Francis on April 21. Acutis was 15 when he died in northern Italy in 2006, after a short bout with leukemia. He has become enormously popular especially among young Catholics who have been flocking to his tomb in Assisi. While he enjoyed regular pastimes for his age — hiking, video games and joking around with friends — he also taught catechism in a local parish and did outreach to the homeless. He used his computer skills to create an online exhibit about more than 100 eucharistic miracles recognized by the church over many centuries. His tomb in Assisi has become a pilgrimage site especially during the 2025 Holy Year underway. It features a glass coffin in which Acutis can be seen dressed in sneakers, jeans and a sweatshirt. In setting the Sept. 7 date, Leo announced Acutis would be canonized along with another Italian Catholic, Pier Giorgio Frassati, who also died young at age 24 after contracting polio. Assisi Bishop Domenico Sorrentino expressed joy Friday at the new date for the canonization and invited Leo to visit the tomb. He said the canonization of Acutis and Frassati would 'put holiness in ordinary life at the center of attention of the church, especially for new generations.' The Vatican requires that the church confirm two miracles attributed to the candidate's intercession in order to proceed with canonization. In Acutis' case, the second alleged miracle concerned the medically inexplicable healing of a Costa Rican young woman who suffered a severe head injury when she fell from a bike in Florence in 2022. Doctors said she was in an irreversible coma. According to Sorrentino's office, the young woman's mother prayed at Acutis' tomb and soon thereafter her daughter's condition improved. She was well enough to visit Acutis' tomb in September. The first alleged miracle occurred in 2013 in Brazil and concerned a young boy afflicted with a grave pancreatic disorder who got better after praying to Acutis. Winfield writes for the Associated Press.


Chicago Tribune
16 hours ago
- Chicago Tribune
Pope Leo XIV to canonize first millennial saint Carlo Acutis in September
ROME — Pope Leo XIV on Friday set Sept. 7 as the rescheduled date to canonize the Catholic Church's first millennial-era saint, Carlo Acutis, in what is expected to be Leo's first saint-making ceremony as well. Leo made the announcement during a meeting of cardinals, known as a consistory, to set the dates for a handful of new saints. Acutis' canonization was originally scheduled for April 27, but was postponed following the death of Pope Francis on April 21. Acutis was 15 when he died in northern Italy in 2006, after a short bout with leukemia. He has become enormously popular especially among young Catholics who have been flocking to his tomb in Assisi. While he enjoyed regular pastimes for his age — hiking, video games and joking around with friends — he also taught catechism in a local parish and did outreach to the homeless. He used his computer skills to create an online exhibit about more than 100 eucharistic miracles recognized by the church over many centuries. His tomb in Assisi has become a pilgrimage site especially during the 2025 Holy Year underway. It features a glass coffin in which Acutis can be seen dressed in sneakers, jeans and a sweatshirt. In setting the Sept. 7 date, Leo announced Acutis would be canonized along with another Italian Catholic, Pier Giorgio Frassati, who also died young at age 24 after contracting polio. Assisi Bishop Domenico Sorrentino expressed joy Friday at the new date for the canonization and invited Leo to visit the tomb. He said the canonization of Acutis and Frassati would 'put holiness in ordinary life at the center of attention of the church, especially for new generations.' The Vatican requires that the church confirm two miracles attributed to the candidate's intercession in order to proceed with canonization. In Acutis' case, the second alleged miracle concerned the medically inexplicable healing of a Costa Rican young woman who suffered a severe head injury when she fell from a bike in Florence in 2022. Doctors said she was in an irreversible coma. According to Sorrentino's office, the young woman's mother prayed at Acutis' tomb and soon thereafter her daughter's condition improved. She was well enough to visit Acutis' tomb in September. The first alleged miracle occurred in 2013 in Brazil and concerned a young boy afflicted with a grave pancreatic disorder who got better after praying to Acutis.


Medscape
16 hours ago
- Medscape
BMI & Nutrition Support Predict Weight Loss in Liver Disease
In patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), higher BMI, nutritionist support, and liver stiffness measurement ≥ 10 kPa were significant predictors of at least 7% weight reduction. METHODOLOGY: Researchers conducted a retrospective study to identify clinical factors that predict successful and sustained weight loss in 897 patients with MASLD (mean age, 61.6 years; 57.1% men; mean BMI, 30.3). They were referred between January 2019 and December 2021, with follow-up occurring between 18 and 24 months at four Italian tertiary centres. The diagnosis of MASLD was confirmed if patients had hepatic steatosis on ultrasound and at least one cardiometabolic risk factor, such as a BMI ≥ 25 or high waist circumference, fasting glucose levels ≥ 100 mg/dL or type 2 diabetes, blood pressure ≥ 130/85 mm Hg, triglyceride levels ≥ 150 mg/dL, or low levels of high-density lipoprotein cholesterol. Baseline and follow‐up data, including demographic, anthropometric, clinical, and biochemical parameters, as well as liver stiffness measurements, were collected from medical records. Details on lifestyle interventions such as Mediterranean diet recommendations, physical activity, and support from a nutritionist were also noted. TAKEAWAY: Over a median duration of 21 months, 18.3% of patients achieved at least 7% weight loss, with 8.5% losing 7%-10% and 9.8% losing more than 10% of their baseline weight. Higher baseline BMI was associated with increased odds of weight loss, with BMI 30-34.9 (adjusted odds ratio [aOR], 1.95; 95% CI, 1.30-2.95) and BMI ≥ 35 (aOR, 2.08; 95% CI, 1.21-3.57) associated with at least 7% weight loss. Nutritionist support (aOR, 2.04; 95% CI, 1.12-3.71), liver stiffness measurement ≥ 10 kPa (aOR, 1.70; 95% CI, 1.07-2.70), and bilirubin levels ≥ 1.2 mg/dL (aOR, 2.12; 95% CI, 1.29-3.51) were independent predictors of achieving at least 7% weight loss. The use of GLP-1 agonists was significantly associated with an increased likelihood of losing at least 7% weight (aOR, 1.85; 95% CI, 1.19-3.80). IN PRACTICE: "Our findings underscore the importance of a comprehensive approach to MASLD management, encompassing medical, nutritional and lifestyle interventions," the authors of the study wrote. "Lifestyle intervention remains crucial for all patients, but for those without predictive factors, close follow-up and early consideration of additional treatments are warranted to maximize therapeutic benefit," they added. SOURCE: This study was led by Nicola Pugliese, Humanitas University, Milan, Italy. It was published online on June 04, 2025, in United European Gastroenterology Journal . LIMITATIONS: This study was retrospective in nature with varying observation periods among the patients. A standardised intervention protocol was lacking across centres, potentially leading to varying management. The absence of systematic data collection from intermediate visits and self-reported data also presented a limitation. DISCLOSURES: This study was supported by funding from the Italian Ministry for Education, University and Research and other projects to an author. The authors reported having no conflicts of interest.